Biopharmx Corp (BPMX) Trading -3.3% Higher

Biopharmx Corp (NASDAQ:BPMX)’s share price traded up 3.3% during trading on Thursday . The company traded as high as $0.31 and last traded at $0.29. 376,857 shares were traded during mid-day trading, a decline of 45% from the average session volume of 681,161 shares. The stock had previously closed at $0.30.

A number of equities analysts have recently commented on the company. Maxim Group reiterated a “buy” rating and issued a $3.00 price objective on shares of Biopharmx Corp in a research note on Friday, June 2nd. Roth Capital set a $3.00 price objective on Biopharmx Corp and gave the stock a “buy” rating in a research note on Saturday, June 3rd. Finally, HC Wainwright set a $3.00 price objective on Biopharmx Corp and gave the stock a “buy” rating in a research note on Thursday, June 15th.

Biopharmx Corp (NASDAQ:BPMX) last issued its earnings results on Wednesday, September 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). Biopharmx Corp had a negative net margin of 28,405.26% and a negative return on equity of 1,847.04%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million.

In other news, major shareholder Franklin Resources Inc bought 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was acquired at an average cost of $0.34 per share, for a total transaction of $85,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

A number of hedge funds have recently modified their holdings of BPMX. Virtu KCG Holdings LLC lifted its position in Biopharmx Corp by 366.2% during the second quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock worth $241,000 after acquiring an additional 395,424 shares during the last quarter. Vanguard Group Inc. lifted its position in Biopharmx Corp by 324.6% during the second quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock worth $927,000 after acquiring an additional 1,478,338 shares during the last quarter. Finally, Vivo Capital LLC lifted its position in Biopharmx Corp by 10.0% during the second quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock worth $6,752,000 after acquiring an additional 1,282,052 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This article was published by Stock Observer and is the property of of Stock Observer. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thestockobserver.com/2017/09/21/biopharmx-corp-bpmx-trading-3-3-higher.html.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply